Table 2.

IC₅₀ (µM) values at 24 h for cell growth inhibition in different cancer cell lines.

Agent	Colon			Breast			Pancreas		Lung		Prostate	Leukemia
	HT-29	HCT 15	SW480	MDA MB 231	SKBR3	MCF-7	MIAPaCa2	BxPC3	A549	H383	LNCAP	Jurkat
SUL	835±75	850±55	710±65	935±35	845±55	975±80	792±68	960±58	212±37	532±38	810±80	650±45
NOSH-SUL	0.095± 0.01	0.11±0.01	0.11±0.009	0.098±0.017	0.12±0.01	0.10±0.007	0.098±0.018	0.12±0.01	0.18±0.015	0.088±0.01	0.09±0.01	0.32±0.03
Enhanced Potency	~8700	~7700	~6400	~9500	~7000	~9700	~8000	~8000	~1100	~6000	~9000	~2000

Colon, breast, pancreas, lung, prostate, and leukemia cancer cell lines were treated with various concentrations of sulindac (SUL) and NOSH-sulindac (NOSH-SUL) as described in Section 2.13. Cell numbers were determined at 24 h from which IC₅₀ values were calculated. The ratios of SUL/NOSH-SUL represent fold-enhancement in potency of NOSH-SUL over SUL. Results are mean±SEM of three independent determinations. In all cell lines, P<0.001 for NOSH-SUL vs SUL.